EXEL – exelixis, inc. (US:NASDAQ)
Stock Stats
News
3/13
08:07 pm
exel
Low
Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation [Yahoo! Finance]
3/13
01:33 pm
exel
Low
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Royal Bank of Canada from $38.00 to $40.00. They now have an "outperform" rating on the stock.
3/13
03:25 am
exel
Low
Qiming-Backed AI Drug Discovery Startup Insilico Medicine Hits Unicorn Status With $110 Million Funding Round [Forbes]
3/12
11:20 am
exel
Low
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
2/25
04:05 pm
exel
Low
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
2/11/2025
04:08 pm
EXEL
1.2%
BEAT
2/11/2025
04:08 pm
EXEL
1.2%
BEAT
2/11/2025
04:08 pm
EXEL
1.2%
BEAT
2/11/2025
04:08 pm
EXEL
1.2%
BEAT
3/13
01:01 pm
Maintains
Outperform
Outperform
RBC Capital
Low
-0.6%
3/13
01:01 pm
Maintains
Outperform
Outperform
RBC Capital
Low
-0.6%
2/24
07:13 am
Downgrades
Overweight
Equal Weight
Wells Fargo & Company
Low
2.1%
2/24
06:06 am
Downgrades
Overweight
Equal-Weight
Wells Fargo
Low
2.7%
2/24
06:06 am
Downgrades
Overweight
Equal-Weight
Wells Fargo
Low
2.7%
3/5
08:48 pm
exel
Low
Form 4 EXELIXIS, INC. For: Mar 03 Filed by: Haley Patrick J.
3/5
05:02 pm
exel
Low
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
3/3
04:18 pm
exel
Low
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
2/28
08:36 pm
exel
Low
Form 4 EXELIXIS, INC. For: Feb 27 Filed by: Smith Julie
2/28
08:36 pm
exel
Low
Form 4 EXELIXIS, INC. For: Feb 26 Filed by: MORRISSEY MICHAEL
Show more
Top News Gainers
4/17 Form 4 EXELIXIS, INC. For: Apr 15 Filed by: SCANGOS GEORGE A 21.5%
6/20 Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha] 9.0%
4/22 Form 4 EXELIXIS, INC. For: Apr 20 Filed by: Haley Patrick J. 7.6%
4/3 Form 4 EXELIXIS, INC. For: Apr 03 Filed by: WYSZOMIERSKI JACK L 6.7%
1/13 Form 8-K EXELIXIS, INC. For: Jan 12 6.6%
1/7 Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 6.1%
7/15 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 6.0%
11/13 Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 6.0%
4/21 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $30.00 price target on the stock. 5.6%
1/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $21.00 price target on the stock, down previously from $22.00. 4.9%
Top News Decliners
10/30 Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update -14.9%
3/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at William Blair. -13.8%
1/24 Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha] -8.7%
7/31 Form 8-K EXELIXIS, INC. For: Jul 31 -6.5%
10/3 Form 4 EXELIXIS, INC. For: Oct 01 Filed by: Schwab Gisela -6.3%
4/9 Form DEF 14A EXELIXIS, INC. For: May 20 -5.2%
4/29 Form 4 EXELIXIS, INC. For: Apr 27 Filed by: MORRISSEY MICHAEL -5.0%
12/5 How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? [Yahoo! Finance News] -4.6%
3/10 Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript) [Seeking Alpha] -4.6%
12/6 Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) [Yahoo! Finance News] -4.5%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3